Healthcare, Pharma & Life Sciences

PulsePoint Extends NPI-Verified HCP Targeting to YouTube

Image
PulsePoint Extends NPI-Verified HCP Targeting to YouTube

New York – September 11, 2026 -- PulsePoint has expanded its Audience Manager platform to YouTube, enabling pharma and healthcare marketers to activate and measure verified, NPI-level physician audiences on the video platform for the first time.

Early campaigns show 1.9x higher click-through rates using verified targeting

In early activations, campaigns using Audience Manager target lists on YouTube generated a 1.9x higher click-through rate compared to broad demographic targeting, according to PulsePoint. The company's DirectMatch technology deterministically matches verified NPI audiences directly onto YouTube campaigns, addressing a gap where video platforms previously lacked prescriber-level precision for media buyers.

Labcorp Acquires MLM Medical Labs, Gains Four-Continent Lab Network

Image
Labcorp Acquires MLM Medical Labs, Gains Four-Continent Lab Network

Burlington, N.C. – September 11, 2026 -- Labcorp (NYSE: LH) has acquired MLM Medical Labs, a central and specialty laboratory provider with operations in the United States, Germany and South Africa, financial terms undisclosed.

Labcorp becomes the only central lab provider with wholly owned facilities on four continents

The deal extends Labcorp's laboratory footprint across North America, Europe, Asia and Africa, combining its global scale with MLM's regional laboratory network and biomarker testing capabilities. The transaction strengthens Labcorp's position as an independent central laboratory services provider for clinical trial sponsors.

QuVa Pharma Acquires CAPS' 503B Compounding Portfolio

Image
QuVa Pharma Acquires CAPS' 503B Compounding Portfolio

Sugar Land, Texas – September 11, 2026 -- QuVa Pharma, Inc. has acquired a portfolio of essential sterile compounded medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business, the companies announced.

QuVa to phase in acquired products starting later in 2026

QuVa expects to begin introducing selected products from the acquired portfolio in phases later in 2026, with plans to expand offerings over the following six months. The deal covers critical medication categories including Cardioplegia, Total Parenteral Nutrition and Heparin.

Anitoa Adds Cloud Connectivity, Hardware Security to Portable qPCR Devices

Image
Anitoa Adds Cloud Connectivity, Hardware Security to Portable qPCR Devices

Sunnyvale, Calif. – September 11, 2026 -- Anitoa Systems, LLC. has integrated cloud connectivity and enterprise-grade security into its portable qPCR molecular testing instruments, enabling remote operation and centralized data aggregation for disease surveillance.

Remote access replaces physical tethering to diagnostic hardware

Users can now control Anitoa's qPCR devices via a secure HTTPS interface through a cross-platform web application, allowing remote data collection, experiment setup, and real-time monitoring from any location. The shift removes the requirement that operators remain physically present with field-deployed instruments.

Harbour BioMed, Windward Bio Post Phase 2 Data for Twice-Yearly Asthma Antibody

Image
Harbour BioMed, Windward Bio Post Phase 2 Data for Twice-Yearly Asthma Antibody

Cambridge, Massachusetts – September 11, 2026 -- Harbour BioMed (HKEX: 02142) and partner Windward Bio reported positive Phase 2 interim results for HBM9378/WIN378, a twice-yearly TSLP-blocking antibody, from the 147-patient POLARIS-1 asthma trial, clearing the path for two Phase 3 studies.

Interim data show up to 174 mL lung-function gain after single dose

The Phase 2 interim analysis, conducted on the first 98 of 147 enrolled patients with uncontrolled moderate-to-severe asthma, found FEV1 increases of up to 174 mL, with a placebo-adjusted mean increase of 256 mL (p=0.033) at Week 24 after a single dose.

Biomarkers for airway inflammation drop sharply

FeNO fell by up to 24 ppb, a 43% reduction (p=0.006), while blood eosinophil counts dropped by up to 200 cells/μL, a 51% decline (p0.0001). Near-maximal effects appeared as early as Week 2 and were sustained through Week 24.

Cartwheel Launches Clinical Program Targeting Youth Screen Addiction

Image
Cartwheel Launches Clinical Program Targeting Youth Screen Addiction

Cambridge, Mass. -- September 11, 2026 -- Cartwheel, the largest school-centered telehealth provider in the U.S., has launched a Screens & Social Media Program to treat students whose sleep, mental health, and school performance are disrupted by digital device use.

Cartwheel clinicians identify escalating digital-stress patterns across nearly 400 school districts

The company reports clinicians have observed students losing sleep to phones, escalating family conflict over screen time, and social media reshaping how kids perceive themselves and peers. The program, in development since spring, was built to move beyond blanket screen-time limits toward individualized clinical treatment.

Bausch Health, YUN Expand Microbiome Skincare to Mexico, EMEA

Image
Bausch Health, YUN Expand Microbiome Skincare to Mexico, EMEA

Laval – September 11, 2026 -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and Belgian biotech YUN have expanded their strategic partnership to Mexico and additional EMEA markets, building on a 2025 launch in Poland.

Partnership adds five new markets across EMEA and Latin America

The collaboration has extended YUN's acne-prone and eczema-prone skincare lines into the Czech Republic, Slovakia, Ukraine and Bulgaria, alongside a fresh entry into Mexico. A further rollout in Kazakhstan is expected in October 2026.

Poland launch deepens into eczema care after 2025 acne debut

In Poland, Bausch Health broadened its dermatology portfolio with YUN's eczema-focused skincare, following last year's introduction of the company's probiotic-based acne-prone skin products.

Lakewood-Amedex CEO to Present at H.C. Wainwright Conference

Image
Lakewood-Amedex CEO to Present at H.C. Wainwright Conference

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

CEO Kelvin Cooper to hold one-on-one investor meetings during three-day conference

Kelvin Cooper, Ph.D., chief executive officer of the clinical-stage biotechnology company, will deliver a virtual presentation and conduct one-on-one meetings with registered investors and potential partners. The sessions will cover Lakewood-Amedex's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Alebund Wins FDA IND Clearance for AP308, First-in-Class IgAN Protease

Shanghai – September 11, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) has received U.S. FDA clearance of its Investigational New Drug application for AP308, a first-in-class engineered recombinant IgA protease targeting IgA Nephropathy (IgAN), moving the candidate from preclinical research into clinical development.

AP308 targets a disease affecting 9.5 million people worldwide

IgAN is the most common primary glomerulonephritis globally, with an estimated 9.5 million patients in 2025, including 5.1 million in China, more than half of the global total, according to China Insights Consultancy. Under current treatment strategies, median kidney survival is approximately 11 to 12 years, and roughly 60% of patients in a Chinese cohort progressed to end-stage renal disease within 15 years of diagnosis, per long-term studies in China and the UK.

Inhibrx's OX40 Drug Doubles Response Rate in Head and Neck Cancer Trial

Image
Inhibrx's OX40 Drug Doubles Response Rate in Head and Neck Cancer Trial

San Diego – September 11, 2026 -- Inhibrx Biosciences reported that its OX40 agonist INBRX-106, combined with pembrolizumab, produced a 48.3% confirmed objective response rate in first-line head and neck squamous cell carcinoma patients, nearly double the 26.5% seen with pembrolizumab alone.

Phase 2 data show the combination therapy nearly doubles response rates versus standard treatment

The randomized Phase 2 portion of the HexAgon study enrolled 68 patients across more than 80 sites in the United States, Europe and Asia, with 63 evaluable for the primary endpoint. Four patients (13.8%) on the combination arm achieved complete responses, compared with zero in the pembrolizumab-only control arm. Six-month progression-free survival reached 72.4% for the combination versus 42.8% for monotherapy, with median PFS of 9.6 months versus 4.9 months as of the August 19, 2026 data cutoff.